Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial | Zendy

Ken Kauffman | Zendy; Dennis E. Doherty | Zendy; Kerwin | Zendy; Matiz-Bueno | Zendy; Knorr | Zendy; Shekar | Zendy; Banerjee | Zendy; Staudinger | Zendy

Open Access

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial

Author(s) -

Ken Kauffman,

Dennis E. Doherty,

Kerwin,

Matiz-Bueno,

Knorr,

Shekar,

Banerjee,

Staudinger

Publication year - 2012

Publication title -

international journal of copd

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 67

eISSN - 1178-2005

pISSN - 1176-9106

DOI - 10.2147/copd.s27319

Subject(s) - medicine , mometasone furoate , copd , formoterol , placebo , spirometry , exacerbation , morning , fixed dose combination , anesthesia , inhalation , corticosteroid , asthma , budesonide , alternative medicine , pathology

A clinical trial of mometasone furoate/formoterol fumarate (MF/F) administered via a metered-dose inhaler in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD) investigated the efficacy and safety of a fixed-dose combination of MF/F.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research